Attached files

file filename
EX-99.2 - SCRIPT OF MANAGEMENT PRESENTATION - cbdMD, Inc.ycbd_ex992.htm
EX-99.1 - PRESS RELEASE - cbdMD, Inc.ycbd_ex991.htm
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) February 13, 2020
 
 
cbdMD, INC.
(Exact Name of Registrant as Specified in Charter)
 
North Carolina
001-38299
47-3414576
(State or Other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
8845 Red Oak Boulevard, Charlotte, NC 28217
(Address of Principal Executive Offices)(Zip Code)
 
Registrant's telephone number, including area code: (704) 445-3060
 
not applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐            
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐            
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☑
 
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common stock
 
YCBD
 
NYSE American
8.0% Series A Cumulative Convertible Preferred Stock
 
YCBD PR A
 
NYSE American
 

 
 
 
Item 7.01 Regulation FD.
 
On February 13, 2020, cbdMD, Inc. issued a press release announcing its financial and operating results for its first fiscal 2020 quarter. A copy of this press release is furnished as Exhibit 99.1 to this report. Also on February 13, 2020, cbdMD, Inc. hosted a conference call to discuss the financial and operating results of its first fiscal 2020 quarter. The script of management's presentation on the conference call is furnished as Exhibit 99.2 to this report.
 
Pursuant to General Instruction B.2 of Form 8-K, the information in this Item 7.01 of Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of cbdMD, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
  
   
 
   
 
Incorporated by Reference
 
  Filed or

 

 
 
 
Date
 
 
 
Furnished
No.
 
Exhibit Description
 
Form
 
Filed
 
Number
 
Herewith
 
Press release dated February 13, 2020
 
 
 
 
 
 
 
Furnished
 
 
 
 
 
 
 
 
 
 
 
 
Script of management presentation for February 13, 2020 conference call
 
 
 
 
 
 
 
Furnished
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
cbdMD, INC.
 
 
 
 
 
Date: February 13, 2020
By:  
/s/ Mark S. Elliott  
 
 
 
Mark S. Elliott, Chief Financial Officer and Chief Operating Officer
 
 
 

 
 
 
 
 
 
 
3